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Single-cell RNA-sequencing (scRNA-seq) allows studying heterogeneity in gene expression in large cell populations.
Such heterogeneity can arise due to technical or biological factors, making decomposing sources of variation
difficult. We here describe f-scLVM (factorial single-cell latent variable model), a method based on factor analysis
that uses pathway annotations to guide the inference of interpretable factors underpinning the heterogeneity. Our
model jointly estimates the relevance of individual factors, refines gene set annotations, and infers factors without
annotation. In applications to multiple scRNA-seq datasets, we find that f-scLVM robustly decomposes scRNA-seq
datasets into interpretable components, thereby facilitating the identification of novel subpopulations.
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Single-cell RNA-sequencing (scRNA-seq) is an estab-
lished tool for assaying variability in gene expression
levels between cells drawn from a population. Cell-to-
cell differences in gene expression can be driven by both
observed and unmeasured factors, including technical
effects such as batch, or biological drivers including cell
type-specific features, such as the stage of T-cell differ-
entiation [1]. Importantly, such technical and biological
factors can act upon the same genes [2, 3], meaning that
they need to be modelled jointly to fully understand het-
erogeneity in scRNA-seq data.
Well-established approaches exist for handling ob-
served factors, such as batch or experimental covariates
[4, 5]. Additionally, methods based on factor analysis
[6–8] and linear mixed models [9, 10] have been devel-
oped to capture unwanted variability that arises from
unmeasured factors, first for conventional ensemble
RNA-profiling experiments and more recently for
scRNA-seq [2]. Examples of unobserved factors that can
explain substantial variation in scRNA-seq include the
number of detected genes in the cell (cellular detection
rate) [3], expression signatures that reflect the quality of
the cell [11], or the cell cycle state [2, 12]. Depending on* Correspondence: fbuettner.phys@gmaill.com; marioni@ebi.ac.uk;
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the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zethe biological question at hand, these factors can mask
other biological sources of variation, or they can them-
selves be of biological interest. There exist several soft-
ware implementations of methods to infer and account
for observed factors and unmeasured factors, including
SEURAT [13], MAST [3], and scLVM [2]. Furthermore,
by using informative marker gene sets, methods based
on SVD and regression have also been employed to re-
construct individual cell state factors, such as the cell
cycle [2, 12]. More recently, Fan et al. [14] introduced
PAGODA, a PCA-based method that allows coordinated
over-dispersion in specific gene sets to be identified.
However, these existing factor methods do not model
errors in how gene sets are defined, and, more import-
antly, they independently fit individual processes and
do not explicitly account for either the presence of add-
itional unannotated biological factors or confounding
sources of variation. Finally, existing factor methods
were motivated by relatively small single-cell RNA-seq
datasets (see Additional file 1 for a comparison to alter-
native factor models). Thanks to recent technological
advances, it is now possible to routinely generate
single-cell RNA-seq datasets containing hundreds of
thousands of cells, which requires computationally effi-
cient methods.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Buettner et al. Genome Biology  (2017) 18:212 Page 2 of 13Results and discussion
To address the aforementioned challenges, we here
propose a factorial single-cell latent variable model
(f-scLVM). Our model jointly infers factors that cap-
ture different sources of single-cell transcriptome
variation, including i) variation in expression attribut-
able to pre-annotated gene sets and ii) effects due to
additional sparse factors that explain putatively mean-
ingful biological effects. In addition to these
biological factors, our model also infers likely con-
founding factors that are expected to affect the
expression profile of the majority of genes (Fig. 1a).
To infer the state of these factors (i.e., whether a given
factor is active in a cell), we employ similar assumptions
as conventional factor analysis or principal component
analysis (PCA). If a factor explains variation in the data,
we assume that the expression levels of all genes
assigned to it co-vary in a consistent manner. This al-
lows the activity of each factor to be inferred from the
data. For annotated factors, we incorporate prior annota-
tion derived from publicly available resources such as
MSigDB [15] or REACTOME [16], thereby assigning
sets of biologically related genes to the same factor. The
selected set of annotated factors depends on the specific
question at hand and can include user-defined gene sets
(“Methods”). The prior annotation is used to inform a
sparse prior on the factor weights. Under this spike-and-
slab prior, genes that are annotated to a factor have a
higher probability of non-zero regulatory weights than
other genes (“Methods”; Additional file 1). This ap-
proach allows the assignment of genes to each factor to
be refined in a data-driven manner. To ensure interpret-
ability, we also assume that only a small number of
changes occur (i.e., that the initial annotation is reason-
ably accurate). For unannotated but biologicallyFactor decomposition 
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Fig. 1 Factorial single-cell latent variable model. a f-scLVM is based on a varia
expression profiles into factors and weights. Gene sets from pathway databas
the activation of unannotated factors. Unannotated factors include both spars
explain confounding sources of variation. b The fitted model can be used for
drivers; ii) visualization of cell states; iii) data-driven adjustment of gene sets; a
unwanted variation and confounding effectsmeaningful factors, we assume generic sparsity such that
these factors drive the variation of a small number of
genes. Finally, we introduce additional dense factors that
have global effects on the expression of large numbers of
genes. Similar to principles applied in population gen-
omics [6, 7], we assume that these factors likely capture
confounding effects.
As well as identifying new factors and updating exist-
ing factor annotation, our model also infers which fac-
tors explain variability in the given dataset. This factor
relevance is inferred by calculating the expected variance
in expression levels across cells using genes assigned to
the factor. To accurately infer these variance
components, f-scLVM can be used in conjunction with
different observation models, thus accommodating both
high-coverage datasets and sparse count profiles that are
typically obtained from droplet-based experiments.
Inference of model parameters, including gene assign-
ments, factor weights, and factor states, is made using
computationally efficient variational Bayesian inference,
which scales linearly in the number of cells and genes.
Although f-scLVM naturally builds on existing factor
models, none of the existing approaches provide these
features within a single model, and in particular the
modelling of gene set annotations has not previously
been considered (see Additional file 1 for full details and
a comparison to existing factor models). The posterior
distributions over model parameters facilitate a wide
range of downstream analyses. These include i) the
decomposition of single-cell transcriptome heterogeneity
into interpretable biological drivers, ii) data visualization
using factor states, iii) the refinement of gene set anno-
tations, and iv) the estimation of a residual dataset,
thereby selectively adjusting for biological or technical
sources of variation (Fig. 1a, b).Factor relevance
Visualisation
Downstream analyses
Model residualsU
na
nn
ot
at
ed
(c
on
fo
un
din
g)
 
fa
cto
rs
d factors Confounding & noise
b
nt of factor analysis, decomposing the matrix of single-cell gene
es are used to annotate a subset of factors, with the remainder enabling
e, likely biological, factors and dense factors, which are more likely to
different downstream analyses, including i) identification of biological
nd iv) estimation of residual expression dataset, thereby adjusting for
Buettner et al. Genome Biology  (2017) 18:212 Page 3 of 13Accurate identification of gene expression drivers and
gene set augmentation
First, to validate f-scLVM we considered a dataset where
the underlying sources of variation are well understood.
We applied f-scLVM to 182 mouse embryonic stem cell
(mESC) transcriptomes, where each cell was experimen-
tally staged according to its position within the cell cycle
[2]. Consequently, across the entire population, we expect
that the cell cycle is the major source of variation. Indeed,
when applying f-scLVM using 44 core molecular pathways
derived from MSigDB [15], the method robustly identified
five factors, including G2/M checkpoint and P53 pathway
(Additional file 2: Figure S1). These two factors could be
used to stratify the cells by their position in the cell cycle
(Fig. 2a). Other methods, including PAGODA, require
additional post-processing steps and infer collinear and
partially redundant factors that less accurately discrimi-
nated cells by cell cycle stage (Additional file 2: Figure S2),
underscoring the importance of jointly modelling all an-
notated and unannotated factors. Furthermore, unlike
existing methodology, f-scLVM enabled data driven re-
finement of gene set annotations (Fig. 2b). The model
modified the G2/M checkpoint factor by adding two
genes, Anln and Kif20a, both of which are well-
characterized cell cycle regulators [17, 18]. Similarly, the
model identified Ptp4a3, a known target of P53 [19], as an
additional member of the P53 pathway.
Next, we used simulations to systematically assess
how robustly our model can identify relevant factors
and complete gene set annotations. Over a wide range
of simulations, where we varied the number of anno-
tated factors and simulated confounders, the degree
of overlap between gene sets, the number of cells,
and the size of the annotated gene sets, we consist-
ently observed that f-scLVM more accurately identi-
fied the true simulated drivers than other methods
based on PCA, linear mixed models, or factor analysis
(Fig. 3a; Additional file 2: Figure S3a–e). Our methoda b
Fig. 2 Model validation using cycling mouse embryonic stem cells. Applica
a Bivariate visualization of the cells using the G2M checkpoint and P53 pat
G2/M phase from the remaining cell population. b Weights for the most im
showing both genes that were pre-annotated by MSIGDB (black) and geneshowed the greatest improvement in performance
over existing methods when multiple unannotated fac-
tors were simulated and when the gene sets explain-
ing the most variance in the data contained a
substantial number of overlapping genes (Fig. 3b). We
also confirmed that f-scLVM was robust to extremely
sparse datasets, typical of droplet-based approaches
(Additional file 2: Figures S3f–h and S11).
Additionally, we considered datasets with simulated
errors in gene set annotation to assess the model’s ability
to adjust these gene sets appropriately (“Methods”). We
observed that the model accurately identified genes that
should be excluded from and added to gene sets (Fig. 3c;
Additional file 2: Figure S4). Unsurprisingly, as the frac-
tion of errors in the gene set annotation increased, the
ability of the model to recover the true sets declined—-
however, in the more realistic setting where only a small
fraction of genes were poorly annotated (1–10%), our
model performed extremely well.Application to neuronal cells
Having validated the performance of f-scLVM, we next
applied it to a population of 3005 neuronal cells [20].
Using gene sets derived from REACTOME pathways
as annotation, our model supported the importance of
a set of factors similar to those identified by methods
such as PAGODA (Fig. 4a), but with important differ-
ences (e.g. innate immune system; Additional file 2:
Figure S5). Additionally, our model suggested a refined
annotation for some of the most relevant gene sets
(Fig. 4a), with, on average, 10% of genes being added
and 3% of genes being removed for the top 20 anno-
tated factors. Furthermore, the model identified unan-
notated factors with a high relevance score (Fig. 4b),
demonstrating the importance of modelling such
factors. We observed that many of these unannotated
factors were sparse and captured differences betweention of f-scLVM to 182 mESCs, experimentally staged for the cell cycle.
hway factors. The inferred G2M checkpoint factor discriminates cells in
portant genes in the P53 pathways and G2M checkpoint factors,
s added by the model (red)
a c
b
Fig. 3 Model validation using simulated data. a, b Accuracy of f-scLVM and alternative methods for recovering the set of simulated drivers of
gene expression heterogeneity. a Receiver operating characteristics (ROC) pooled across different simulated datasets (Additional file 2: Table S1).
b Area under the ROC curve (AUC) when simulating an increasing number of unannotated factors not included in the pathway database (left)
and when considering increasing overlap between simulated gene sets (right). c Ability of f-scLVM to augment gene sets when an increasing
proportion of genes in the annotation were falsely assigned. Shown is an AUC for correctly including genes omitted from gene sets (red) and for
removing genes that were incorrectly annotated (blue). Bar plots in b, c show the median AUC across 50 repeat experiments per setting with error
bars corresponding to 25 and 75% percentiles. FPR false positive rate, TPR true positive rate
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annotations (Additional file 2: Figures S5 and 6a–c).
The top ranked annotated processes separated the
cells into well-defined groups, with the endothelial-
mural cells being stratified into two populations by the
muscle contraction factor (Fig. 4c). Notably, our model
augmented the corresponding gene set by activating
several genes that have previously been implicated in
muscle contraction but that were not present in the
pre-defined REACTOME gene set (Fig. 4d). Among
the 13 identified genes were several known markers of
vascular smooth muscle cells, including Rgs4, Mtfge8,
and Notch3 [21–24]. A second major driver identified
by f-scLVM was the innate immune system factor,
which, in particular, separated microglia (nervous sys-
tem immune cells) from the remaining cell types
(Fig. 4c). Moreover, similar to the muscle contraction
factor, the gene set was also augmented with meaning-
ful genes (Additional file 2: Figure S6d).
In addition to the populations of neurons character-
ized by Zeisel et al. [20], we also applied f-scLVM to a
variety of other datasets, identifying relevant factors
that explained complementary axes of variation,
augmenting gene sets, and observing that a consider-
able proportion of the variance explained could be
attributed to unannotated factors (Additional file 2:
Supplementary analyses and Figures SN1–3). We also
assessed the robustness of the annotated factors identi-
fied by f-scLVM (Additional file 2: Figure S10).Scalability to datasets with tens of thousands of cells
Finally, given the increasing trend to generate scRNA-
seq datasets containing tens to hundreds of thousands
of cells, we contrasted the computational efficiency of
our model with a variety of factor analysis models
(Figure 5a; Additional file 2: Figure S7). We observed
that, irrespective of the number of cells, f-scLVM had
a lower runtime than other approaches, with a linear
scaling time in the number of cells as opposed to
quadratic or even cubic relationships for other ap-
proaches. Similarly, f-scLVM has a linear time-scaling
in the number of genes (Additional file 2: Figure S7).
As a consequence, f-scLVM can be applied to large-
scale droplet-derived datasets.
To illustrate this, we applied f-scLVM to expression
profiles from 49,300 retinal cells profiled using Drop-
seq [13]. Again, unannotated factors explained
substantial variation in the data, where most of this
variation could be attributed to a single factor that
affected a large number of genes (Additional file 2:
Figure S8a), suggesting that it may correspond to con-
founding effects. Indeed, this factor was correlated
with the cellular detection rate (Additional file 2:
Figure S8f ), a known confounding feature of scRNA-
seq datasets [3]. As previously, our model identified
biologically plausible processes, including GPCR
signalling and transmission across chemical synapses,
as explaining variability in the data (Additional file 2:
Figure S8a).
ca
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b
Fig. 4 Application of f-scLVM to neuronal cells. a Factor relevance and gene set augmentation for the most important 30 factors identified by
f-scLVM based on REACTOME pathways. Bottom panel: Identified factors and corresponding gene set size ordered by relevance (white = low relevance;
black = high relevance). Top panel: Gene set augmentation, showing the number of genes added (red) and removed (blue) by the model for each
factor. b Breakdown of the cumulative factor relevance of annotated and unannotated factors (see also Additional file 2: Figure S5). c Bivariate
visualization of cells using the factors muscle contraction and innate immune system. Colours correspond to cell types identified in [20]; numbers
denote relative factor activities inferred by the model. d Weights for the most important genes in the muscle contraction factor, showing both genes
that were pre-annotated by REACTOME (black) and genes added by the model (red)
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the residual dataset generated after regressing out the
effect of the unannotated, confounding, factor
(“Methods”) [25]. When focusing on a set of six re-
lated and well defined cell types identified in the pri-
mary analysis—Müller glia, astrocytes, fibroblasts,
vascular epithelium, pericytes, and microglia—the re-
sidual data revealed two subpopulations of astrocytes
(Fig. 5b, c), as well as two subpopulations of micro-
glia (Additional file 2: Figure S8b–d). In total, 1024
genes were differentially expressed between the two
astrocyte populations (Wilcoxon rank sum test, false
discovery rate (FDR) < 10%; Additional file 3). Thesewere enriched for processes related to immune
response and activation of astrocytes, such as inflam-
matory response [26], BMP signaling pathway, and
cellular response to BMP [27, 28] (Additional file 2:
Table S2), and included known genes related to react-
ive/inflammatory processes in astrocytes, such as Ccl2
[26]. In addition, BMP signalling is known to activate
distinct downstream transcription factors, including
Stat3 and Smad5, which show the expected pattern of
behaviour between the two newly identified popula-
tions [29] (Fig. 5d). Taken together, these results show
that f-scLVM can be used to infer biological and
confounding factors from large datasets.
a d
b c
Fig. 5 Application of f-scLVM to large-scale scRNA-seq datasets. a The empirical runtime when applying f-scLVM and alternative factor models
(RUV, SVA, scLVM, PAGODA) to datasets with increasing size. f-scLVM scales linearly in the number of cells, enabling its use on large datasets with
up to 100,000 cells. None of the existing methods could be applied to the largest dataset. Error bars denote plus or minus one standard deviation.
b-d Application of f-scLVM to 49,300 retina cells profiled using Drop-Seq. b Visualization of a subset of 2145 cells using a non-linear t-SNE
embedding. Colours correspond to cell types identified in [13]. c Analogous t-SNE embedding as in b, but on residual data (“Methods”; Additional
file 2: Figure S8). The analysis on the residual dataset revealed additional substructure between cells, including two sub clusters of astrocytes (C1
and C2). d Genes and factors that were differentially expressed (false discovery rate < 10%) between the newly identified astrocyte clusters
highlighted in c. The colour code is consistent with panel c; grey dots denote outlying cells. Box plots show median expression and the first and
third quartile, whiskers show 1.5 × the interquartile range above and below the box
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sets and investigated the nature of unannotated factors
inferred by our model. We observed, as above, that these
factors were often associated with technical experimental
features that have previously been suggested to underpin
variability in scRNA-seq data, including the number of
expressed genes and sequencing depth (Additional file 2:
Figure S9). However, these associations were often weak,
suggesting that the inferred hidden factors help to
capture additional unwanted variation that cannot be
assigned to measured covariates.
Conclusions
Here, we have proposed a scalable factor analysis
approach to comprehensively model the sources of
single-cell transcriptome variability. Unique to our
model is the ability to jointly infer both annotated and
unannotated factors, including confounders, and toaugment predefined gene sets in a data driven manner.
Additionally, f-scLVM is computationally efficient,
allowing analysis of very large datasets containing hun-
dreds of thousands of cells.
We have validated our model using simulations as well
as real data where the sources of transcriptome variabil-
ity are well understood. Subsequently, we have applied
the model to a range of different experimental settings,
demonstrating its ability to infer drivers of transcriptome
variation, adjust gene sets to discover new marker genes
and account for hidden confounding factors in the data.
Of course, our model is not free of limitations. A gen-
eral challenge for any method is to reliably differentiate
confounding factors from biological signal. f-scLVM ad-
dresses this through specific assumptions on the effect
of these factors (sparse versus dense) in conjunction
with leveraging gene set annotation from pathway data-
bases. Nevertheless, it is critical to interpret the model
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context of a given dataset.
A second potential caveat is the lack of accurate gene
set annotation, which will necessarily impact the quality
of the results. To mitigate this challenge, f-scLVM
models possible errors in the annotation explicitly and
augments gene sets in a data driven manner. However,
such inferences have limitations. One important chal-
lenge is collinearities between annotated factors and true
biological differences. For example, if cells in different
stages of the cell cycle are systematically associated with
different cell types, the results from gene set refinements
may be misleading and collapse two distinct biological
processes into a single factor.
Other technical aspects of the model could be improved
in the future. The noise model we use at present is based
on a Hurdle model [3], which could be adapted to more
specifically model the noise properties of different experi-
mental platforms. Also, our model is intrinsically linear
and in particular it assumes that the inferred factors have
linear additive effects on gene expression. It would be pos-
sible to model interactions between factors or different
conditions, for example to assess whether a specific path-
way is more active in a defined subset of cells. Extensions
of f-scLVM in this direction will be an important area of
future work. Finally, we note that f-scLVM could also be
applied to other data modalities. In parallel to scRNA-seq,
there are increasingly opportunities to model single-cell
epigenome variation data, including single-cell DNA
methylation profiling [30, 31], single-cell ATAC-seq [32]
and multi-omic methods [33, 34].
Methods
The factorial single-cell latent variable model (f-scLVM)
f-scLVM is based on a variant of sparse factor analysis,
decomposing the observed gene matrix into a sum of
contributions from C measured covariates, A annotated
factors, whose inference is guided by pathway gene sets,
and H additional unannotated factors:
Y ¼
XC
c¼1
uc VcT
|ﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄ}
cell covariates
þ
XA
a¼1
pa Ra
T
|ﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄ}
annotated factors
þ
XH
h¼1
sh Qh
T
|ﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄ}
unannotated factors
þ Ψ: ð1Þ
Here, Y denotes the gene expression matrix where rows
correspond to each of N cells and columns correspond to
G genes. The vectors uc, pa, and sh correspond to known
cell covariates, as well as cell states for annotated and un-
annotated factors, and Vc, Ra, and Qh are the correspond-
ing regulatory weights of a given factor on all genes. The
matrix ψ denotes residual noise, with its specific form de-
pending on the noise model employed (see below). For the
statistical derivation (see also Additional file 1), we express
the model in Eq. 1 using matrix notation, collapsing thefactors into a factor activation matrix X = [u1,.., uC, r1,..,
rA, s1, …, sH] (with the comma denoting concatenation of
columns), where each factor is enumerated using an indi-
cator k = 1.. K, and K denotes the total number of fitted
factors K = C +A +H. The analogous matrix representa-
tion is used for weightsW, resulting in:
Y ¼ XWT þ ψ:
Known covariates, annotated factors, and unannotated
factors then correspond to different distributional as-
sumptions on the column vectors of the matrices X and
W. For brevity, we omit the cell covariates in the deriva-
tions below (Additional file 1).
We place standard multivariate normal prior distribu-
tions on the factor states of both annotated and unanno-
tated factors. For annotated factors, we employ two
levels of regularization on the corresponding columns of
the weight matrix W. First, gene set annotations are
used to inform a regulatory sparseness prior on the rows
of W [35], thereby confining the inferred weights to the
set of genes annotated in the pathway database. Second,
we employ regularization of the overall variance ex-
plained by individual factors (factor relevance), thus
allowing the model to deactivate factors that are not
needed to explain variation in a given dataset.
Regulatory sparseness prior
Gene set annotations inform a spike and slab mixture
prior on the elements of W. The regulatory weight of
factor k on gene g is modelled using a Normal distribu-
tion (with factor-specific precision αk) if the regulatory
link is active (zg,k = 1), and a delta distribution otherwise
to force the weights of inactive regulatory link to zero:
p wg;k jzg;k
  ¼
(
N

wg;k j0; 1=αkÞ if zg;k ¼ 1
δ0 wg;k
 
otherwise:
ð2Þ
The true state of the indicator variable zg,k, which deter-
mines whether factor k regulates gene g, is unobserved.
However, pathway annotations provide partial evidence
which can be used to infer the most likely state of zg,k:
p Ing;k jzg;k
 
¼
Bernoulli Ing;k ¼ 1 j1−FPR
 
if zg:k ¼ 1
Bernoulli Ing;k ¼ 1 j FNR
 
otherwise
:
8
<
:
Here, Ig,k
n is a binary variable denoting whether gene g
is annotated to pathway k in the annotation database.
The pathway annotation is modelled as observed data
for each individual cell, thereby ensuring that the relative
contribution of the annotations is independent of dataset
size (Additional file 1). The rate parameter FPR corre-
sponds to the probability of a false positive assignment
and FNR denotes the probability of a false negative as-
signment. In the experiments, we use FNR = 0.001 and
Buettner et al. Genome Biology  (2017) 18:212 Page 8 of 13FPR = 0.01. Because the annotation information is mod-
elled in the likelihood, the prior on the indicator vari-
ables is uninformative, zg,k ~ Bernoulli(0.5).
During inference, the posterior distribution of the indi-
cator variables zg,k is then estimated jointly from the
observed expression data and the annotation. Once
trained, the marginal posterior estimates of zg,k allow
identification of genes that are added to or removed
from a particular factor, thereby augmenting the annota-
tion in a data-driven manner.
Automatic relevance determination for determining factor
relevance
In addition to the regulatory sparseness prior, f-scLVM
uses automatic relevance determination (ARD) [36] to
regularize the variance explained by individual factors.
This is achieved by placing a hierarchical prior on the
precision of the normal priors for active links (Eq. 2) αk
~ Γ(a, b). The precision αk will be large for factors with
low relevance, which corresponds to low prior variance,
thus driving the regulatory weights to zero. The prior
variance 1/αk can also be interpreted as a measure of the
regulatory impact of a factor and corresponds to the ex-
pected variance explained by the factor, for the subset of
genes with a regulatory effect (see “Downstream ana-
lysis” section).
Modelling unannotated factors
In addition to annotated factors, f-scLVM jointly esti-
mates the effect of a fixed number of unannotated fac-
tors. In the experiments, we consider two types of
unannotated factors. First, to infer likely confounding
factors, we assume that confounding factors have broad
effects on large proportions of all genes, a principle that
is widely used in population genomics [6, 7]. This prior
belief is encoded using the Bernoulli prior zg,k ~
Bernoulli(0.99), as a result of which the weights for these
factors are effectively only regularized by the ARD prior.
Second, f-scLVM allows inference of an additional set of
sparse unannotated factors. These factors can, for ex-
ample, be used to model additional biological variation
that is not well captured by the factors in the annotation.
These sparse factors are modelled using a Bernoulli prior
that favours a small number of active links zg,k ~
Bernoulli(0.01). The decision on how many factors of each
type to consider can be guided by heuristics and diagnos-
tics; see section “Diagnostics and f-scLVM parameter set-
tings” for details on the selection of specific models.
Noise model
f-scLVM supports alternative noise models to accommo-
date different RNA-sequencing protocols. First, the
standard option is the log normal noise model, where
the expression matrix Y consists of log count valueswhich are modelled assuming i.i.d. heteroscedastic resid-
uals ψ (Additional file 1). We infer different residual var-
iances for each dimension (gene), thereby accounting for
varying extents of over-dispersion and enabling the
model to deactivate some input dimensions, an approach
widely adopted in conventional factor analysis [37].
In order to model the zero-inflation resulting from
prominent dropout effects for protocols such as Drop-seq
[13], f-scLVM can alternatively be run in conjunction with
a zero inflation (Hurdle) noise model. A separate Bernoulli
observation noise model is used, when no expression (zero
count values) is observed for any specific expression value,
while all remaining values are modelled using the afore-
mentioned log Gaussian noise model. Formally, we define
the factor analysis model on latent variables, F = XWT, and
use the compound likelihood:
P yn;g jf n;g
 
¼
1
1þ exp f n;g
  if yn;g ¼ 0
N log yn;g þ 1
 
jf n;g ; σ2g
 
otherwise
8
><
>:
where, analogous to the log normal noise model, yn,g
corresponds to log count observations. Note that in the
absence of zero counts, this noise model reduces to the
basic noise model.
Finally, if zero-inflation is less likely, for example in
deeply sequenced datasets with larger quantities of start-
ing material per cell, f-scLVM can also be used in con-
junction with a classic Poisson noise model. The
inference approach is analogous to the dropout model;
however, assuming the following likelihood model:
P yng jf ng
 
¼ λ f ng
 yng e−λ f ngð Þ
;
with link function λ f ng
 
¼ log 1þ ef ng  and yn,g now
denoting raw count values.
Parameter inference
Closed-form inference in sparse factor analysis models
such as f-scLVM is not tractable. In order to achieve
scalability to large numbers of cells and genes, we em-
ploy deterministic approximate Bayesian inference based
on variational methods [38]. The core idea of variational
Bayes is to approximate the true posterior distribution
over all unobserved variables using a factorized form.
This assumption of (partial) factorization of the poster-
ior allows derivation of an iterative inference scheme,
updating posterior distributions for individual parame-
ters in turn, given the state of all others. An important
design choice in f-scLVM is to couple the approximate
posterior over the regulatory sparsity indicator zg,k and
the model weights wg,k. For full details and the update
equations for the f-scLVM see Additional file 1.
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The fitted f-scLVM model facilitates a range of different
downstream analyses.
Factor relevance The relevance of different factors, in-
cluding annotated pathway factors, is deduced from the
ARD variance 1/αk, which corresponds to the expected
explained variance of factor k for the subset of genes
with a regulatory effect (e.g. Fig. 3a, b).
Visualization The posterior distribution over the in-
ferred factors X allows cell states to be visualised (e.g.
Fig. 4c). This is possible for both annotated and unanno-
tated factors. In the latter case, sparse unannotated fac-
tors frequently tend to capture additional structure
between cell types (Additional file 2: Figures S5 and S6).
Gene set refinement By comparing the posterior distri-
bution on the indicator variables zg,k with the prior gene
set annotations Ig,k, it is possible to identify individual
genes that were added to or removed from a pathway
factor during inference (e.g. Fig. 4a, d). We use the pos-
terior threshold of 0.5 to identify genes that were added
to or removed from a gene set.
Estimation of residual expression datasets and
imputation The learned factor X in combination with
the corresponding regulatory weights W can also be
used to calculate residual datasets where the effects of
selected factors are removed, or to obtain imputed data-
sets. When using the dropout noise model, expression
residuals are estimated based on the latent expression
values F (see “Noise model” section above). In this in-
stance the model implicitly uses the dropout noise
model to impute zero values prior to estimating expres-
sion residuals (Additional file 1).
Relationship to other factor analysis models
Several existing factor analysis methods are related to
f-scLVM. First, factor analysis with dense unannotated
factors is used to adjust for unwanted variation in
bulk datasets, including SVA [6], RUV [8], and PEER
[7]. However, unlike f-scLVM, these methods do not
model annotated factors using gene sets and hence
are not designed for identifying biological drivers.
Second, methods such as PAGODA [14] use gene set
annotations to identify interpretable factors. However,
this does not explicitly model variation outside the anno-
tation, and it infers factors sequentially, which can lead to
collinearities (Additional file 2: Figure S2b, e, f). Finally,
there exist methods based on sparse factor analysis, in-
cluding non-parametric methods and factor models that
account for the specifics of single-cell transcriptome noise.
f-scLVM is related to these variants of factor analysis, allof which are based on a linear additive model. Again, these
methods do not utilize gene set annotations. f-scLVM gen-
eralizes many of these methods and, in particular, offers
favourable computational efficiency. For further details
and a detailed comparison of the features offered by
different methods see Additional file 1: Section 2.Implementation of alternative methods
We compared the performance of f-scLVM to that of
existing factor models. First, we ran PAGODA using the
scde R package [14]. Briefly, PAGODA infers a gene-
specific residual variance by deriving cell-specific error
models accounting for dropout effects. This error model
is then used to perform weighted PCA [39] on individual
gene sets in turn, followed by a ranking of gene sets
based on the explained variance of the leading PC. We
also considered the single-cell latent variable model
(scLVM [2]), which analogously to PAGODA infers inde-
pendent low-rank factors based on predefined gene sets.
The proportion of average variance explained by individ-
ual factors for the set of annotated genes, as determined
using the variance decomposition described in [2], was
used to rank factors. A second class of methods we com-
pared to are factor models that do not explicitly incorp-
orate gene set annotations. Among these we used a
conventional PCA fitted to the set of all expressed genes.
Second, we applied the recently proposed Zero-Inflated
Factor Analysis model (ZIFA) [40], a factor analysis im-
plementation that explicitly models dropout events.
Third, we applied a sparse factor analysis model based
on the Indian buffet process (IBP), a non-parametric
model that automatically infers the most appropriate
number of sparse factors. None of these methods anno-
tate the inferred factors and hence we implemented a
post-processing step based on a gene set enrichment
(using Fisher’s exact test based on the 40% of genes with
the highest absolute weights; python package xstats.en-
richment) to annotate the learnt factors using the same
gene sets used to fit f-scLVM. We then used the enrich-
ment p-value to rank the annotated individual gene sets
as potential biological drivers.
For runtime assessments, we additionally considered
two approaches to account for unwanted variation. SVA
timings were reported using the R implementation of
the SVA package [41], considering a fixed number of
surrogate variables that correspond to the true number
of simulated factors. RUV runtime results were obtained
using the RUV2 function from the R implementation,
which estimates and adjusts for unwanted variation
using control genes. Runtime estimates were obtained
using the time module in python (time() function) and
the proc.time() function in R; all simulations were run
on eight cores of an Intel Xeon 2.60 GHz CPU.
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Choice of the gene set annotations used in the model
In principle, large numbers of annotated factors can be
inferred based on large gene set annotations. Factors
that correspond to inactive pathways will be deactivated
during inference. However, in practice there are trade-
offs such that compact gene sets can be advantageous as
the model scales computationally linearly with the num-
ber of factors. Empirically, we found that databases with
tens to hundreds of annotated pathways result in a good
trade-off between resolution and run-time. In particular,
the MSigDB core processes database (hallmark gene sets
H) consists of a comprehensive list of 50 pathways,
allowing for a good resolution in relatively short run-
times. For a more fine-grained analysis, we chose the
REACTOME database consisting of 674 pathways.Diagnostics and f-scLVM parameter settings
By default f-scLVM is fitted using annotated factors
guided by gene set annotations and additional dense un-
annotated factors that capture unwanted variation. How-
ever, for some datasets this set of factors may not be
sufficient to explain the observed heterogeneity, e.g. be-
cause potential differences between cell types may not
be well reflected by the provided annotations. In this
case, it is advised to infer an additional set of sparse un-
annotated factors. A suitable diagnostic for this decision
are excessive augmentations of the annotated gene sets
such that the inferred factor is unlinked to the annotated
biological process. In the software implementation of f-
scLVM, sparse unannotated factors are activated if the
standard model changes (gains or losses) at least 100%
of annotations for at least one annotated factor. For
sparse and dense unannotated factors, we considered
five and three factors by default, respectively. Note that
because the ARD prior allows unused factors to be deac-
tivated, the model is robust with respect to the number
of dense unannotated factors, provided a sufficiently
large number is inferred (Additional file 2: Figure S3i).Filtering and gene selection of single-cell RNA-seq datasets
We applied f-scLVM to datasets filtered for high-quality
cells and variable genes (see also individual datasets
below). Analogous to commonly applied filtering steps
for t-SNE and other scRNA-seq visualization ap-
proaches, we recommend applying f-scLVM to genes
that vary significantly across the set of cells. This set of
genes can be identified based on ERCC spike-ins or a
mean-CV relationship of endogenous genes. Genes in
the tail of the variance distribution are dominated by
technical sources of variation and hence can be
discarded without loss of information.Simulation study
We simulated gene expression matrices based on a linear
additive model, an assumption that is motivated by the
generative model that underlies both f-scLVM and exist-
ing alternative approaches, all of which are based on vari-
ants of linear factor analysis models (Additional file 1).
We simulated effects from between three and ten active
pathway factors with partially overlapping gene sets for
each factor (see below), additional effects due to unknown
confounding factors, and observation noise. We consid-
ered a total of 44 simulation settings, considering variable
dataset sizes (cell count), variable numbers of active path-
way factors, and increasing numbers of simulated unanno-
tated confounding factors. Additionally, we varied the
overlap of genes annotated to individual pathways and the
size of the individual gene sets and added varying degrees
of noise in the annotation provided to each respective
model by simulating a certain proportion of false nega-
tive/false positive annotations and by swapping genes
between active factors (see Additional file 2: Table S1 for
full details of simulation parameters).
Each simulated dataset consisted of between 20 and
500 synthetic cells and 6000 genes. Gene set sizes were
determined by sampling from REACTOME pathways
(considering 421 pathways with 20 to 933 genes). When
ranking active pathways, we compiled an annotation
consisting of the true drivers and an additional set of 15
non-active pathways as a negative set, and provided it to
each considered method. Confounding factors, if simu-
lated, were generated analogously to the approach
described in [10], assuming broad effects affecting
between 400 and 3000 randomly selected genes. The
annotations of simulated pathways were generated
sequentially, ordering pathways by decreasing size and
drawing genes with a selected overlap to already existing
pathways. Pathways were simulated to have overlapping
gene sets, between 0.0 (no overlap) and 0.7 (70% of the
genes overlap). To test for the impact of the size of gene
sets, we additionally considered sampling REACTOME
pathways with between 20 and 50, 50 and 100, and 100
and 200 genes. To assess the robustness of f-scLVM to
incorrect gene set annotations, we simulated between 1
and 50% of false negative and between 1 and 10% false
positive genes in the gene set annotations of individual
factors. We also considered more challenging mis-
annotations by introducing gene-swaps between pairs of
active factors (for between 1 and 25% of all genes).
Factor activations as well as non-zero regulatory weights
were drawn assuming a unit variance normal distribu-
tion. Residual noise was simulated as normally distrib-
uted with standard deviation 0.1. When dropout was
simulated, we considered two alternative dropout mech-
anisms. First, we model a threshold effect by setting all
values less than a given threshold to 0; this reflects a
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cannot be detected reliably. Second, we considered
modelling the probability of dropout events as a func-
tion of the true expression level, assuming an exponen-
tial relationship [40]: pdrop = exp(−λfng
2 ), with fng being
the latent expression level introduced above and λ the
exponential decay parameter. Both dropout processes
are simulated, where each setting is parameterized by λ
and the threshold value, which corresponds to the
lower limit of detection. For each simulation setting, 50
independent datasets were generated.
To assess the performance of f-scLVM and alternative
methods, we consider the receiver operator characteristics
(ROC) for identifying the true simulated drivers. For f-
scLVM the factor relevance was used to rank factors.
Analogous metrics were derived for all alternative methods
(see “Implementation of alternative methods” section).
Additionally, we assessed the ability of f-scLVM to
augment corrupted gene set annotations (Fig. 2c;
Additional file 2: Figure S4). We evaluated the ability of
the model to correct the false positive and false negative
annotations separately.
Staged mouse embryonic stem cells
The set of 182 mESCs staged for the cell cycle have pre-
viously been described in [2]. Briefly, cells were cultured
in serum-free NDiff 227 medium (Stem Cells Inc.) sup-
plemented with 2i inhibitors and sorted by cell cycle
phases (G1, S G2/M) using FACS and Hoechst staining
(Hoechst 33342; Invitrogen). Cells in all three cell cycle
stages were profiled using the Fluidigm C1 system. We
followed the pre-processing and normalization approach
as previously described [12] and considered log-
transformed and size-factor adjusted (geometric library
size on endogenous genes) gene expression counts for
6635 variable genes for analysis. Additional results
shown in Additional file 2: Figure S1c, d were obtained
when considering a size-factor normalization based on
ERCC spike-ins, which retains variation in the overall
amount of mRNA per cell. f-scLVM was applied using
44 gene sets derived from MSigDB (after filtering;
Additional file 1). We further applied PAGODA to the
raw count data of the 182 cells using the R package scde
with standard settings [14].
Zeisel et al. dataset
We analysed log-transformed gene expression values
of 3005 single neurons sequenced using a protocol
with unique molecular identifier [20]. We followed the
pre-processing and filtering steps from the primary
publication, resulting in 7097 variable genes. f-scLVM
was applied using 161 annotations from the REAC-
TOME database (after filtering; Additional file 1), pro-
viding a high-resolution annotation. Following modeldiagnostics steps (see “Diagnostics and f-scLVM par-
ameter settings”), an additional five sparse unanno-
tated factors were added and fitted jointly with the
remaining factors (Additional file 2: Figure S5).
Residual datasets were generated by regressing out the
effect of the most relevant unannotated factor
(Additional file 2: Figure S6e–h).
Retina cells
We considered the normalized, log-transformed ex-
pression values of 49,300 retina cells as described in
[13]. We considered all expressed genes, using the
dropout noise model in f-scLVM to account for low se-
quence coverage. We considered gene sets from the
REACTOME database. Because of the size of the data
set, we used factor pre-screening to reduce the set of
factors before training, retaining 50 gene sets
(Additional file 1). To generate expression values cor-
rected for confounding factors, we considered residual
gene expression profiles, regressing out the effect of
the most relevant unannotated dense factor. These re-
sidual data are available from [25]. Visualizations of
corrected and raw expression values of six related cell
types identified in the primary publication (Müller glia,
astrocytes, fibroblasts, vascular epithelium, pericytes,
and microglia) were obtained using t-SNE. The analysis
of differentially expressed genes and factors was car-
ried out using the Wicoxon rank sum test.
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